Abpro Holdings, Inc. (ABP)

Market Cap	20.52M
Revenue (ttm)	183,000
Net Income (ttm)	-22.48M
Shares Out	80.17M
EPS (ttm)	-0.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,107,219
Open	0.2500
Previous Close	0.2521
Day's Range	0.2461 - 0.2585
52-Week Range	0.1516 - 11.1900
Beta	0.03
Analysts	Strong Buy
Price Target	4.00 (+1,462.5%)
Earnings Date	Aug 13, 2025

About ABP

Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company’s lead product candid...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: ABP
• Website: https://abpro.co

Financial Performance

In 2024, Abpro Holdings's revenue was $183,000, an increase of 50.00% compared to the previous year's $122,000. Losses were -$17.41 million, 48.7% more than in 2023.

Analyst Summary

According to one analyst, the rating for ABP stock is "Strong Buy" and the 12-month stock price target is $4.0.

Price Target

$4.0

(1,462.50% upside)

Analyst Consensus: Strong Buy